Entrada Therapeutics (NASDAQ:TRDA) Cut to “Sell” at Wall Street Zen
Wall Street Zen downgraded shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday. Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Entrada Therapeutics in a report on Tuesday, May 20th. One […]
Wall Street Zen downgraded shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday. Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Entrada Therapeutics in a report on Tuesday, May 20th. One […]
